Search This Blog

Thursday, May 28, 2026

'US, Iran said to reach deal, awaiting Trump's approval'

 The United States and Iran have reached a deal on a memorandum of understanding, which is set to extend the ceasefire by 60 days and kick off the negotiations concerning Iran's nuclear program, Axios reported on Thursday, citing two US officials. The negotiators are now reportedly waiting for US President Donald Trump to give his final approval.

According to the report, the US president was briefed on the deal, with the terms said to have been mostly agreed to on Tuesday, and he has asked for a few days to consider it. The deal reportedly includes Iran's commitment not to pursue a nuclear weapon, while the issue of its highly enriched uranium is set to be the first topic of discussion during the 60-day negotiation window.

Under the new agreement, the maritime traffic through the Strait of Hormuz is said to be "unrestricted," with Iranians having to remove all mines from the waterway within 30 days.

https://breakingthenews.net/Article/US-Iran-said-to-reach-deal-awaiting-Trump's-approval/66390474

Teladoc partners with Walmart to expand virtual care services

 Teladoc Health is expanding its retail partnerships with a new tie-up with Walmart to offer its virtual care services through the company's Better Care Services platform.

Walmart launched the digital health platform earlier this year as a one-stop hub to connect customers to third-party telehealth providers. In April, the retail giant expanded the platform's weight management offerings, including access to GLP-1 medications.

For Teladoc, the collaboration with Walmart will enable the retailer's customers to access virtual urgent care, dermatology and nutrition services with insurance benefit and cash-pay options. This follows the January launch of Teladoc Health’s BetterHelp mental health offering on Walmart’s Better Care Services platform.

For a cash-pay price of $89 per visit, Walmart customers can access Teladoc Health’s virtual clinical practice to connect with providers to treat a range of common conditions, including sinus infections, pink eye, UTIs, cold and flu symptoms. For dermatology visits, patients can upload photos of a skin issue to get help for rashes, sunburns, skin infections and other issues. Within 24 hours, a board-certified dermatologist will carefully review, share a diagnosis and custom treatment plan, according to Teladoc Health.

For the company's nutrition services, customers can work one-on-one with a registered dietitian to receive a personalized nutrition guide, plus support for diabetes, weight management and prenatal nutrition.

If a customer needs a prescription, the medication can be sent to a pharmacy, including Walmart's pharmacy services, which enables same-day delivery and, in many locations, there is one-hour prescription delivery, the companies said.

More than 100 million people have access to Teladoc Health's services and the company works with more than 100 U.S. health plans.

The collaboration brings together the biggest retailer in America with the largest nationwide network of virtual care providers from Teladoc Health to reach people where they already are, making care more convenient and affordable, Teladoc Health executives said.

"Millions of Americans already turn to Walmart for their everyday health and wellness needs so this partnership creates a new touchpoint, really bringing our trusted clinical network and services directly into the Walmart experience," Kelly Bliss, Teladoc Health’s President of U.S. Group Health, told Fierce Healthcare. "It's a logical partnership. We want to be where Americans already go when making decisions around their health and this partnership combines the scale and reach and makes quality virtual care available where they're already making those health decisions."

Teladoc Health's service also includes quick insurance eligibility checks for the one in three Americans already covered through Teladoc Health via employers or health plans.

"Healthcare should be easier to access, easier to understand and more affordable," said Leslie Fletcher, Vice President, Strategy and Partnerships, Walmart U.S. Health & Wellness, in a statement. "By adding Teladoc Health we’re continuing to expand Better Care Services with more options for care, paired with fast, convenient access to everyday health needs and prescriptions." 

Teladoc Health has been growing its retail and platform partnerships. The virtual care company integrates its chronic condition management service into Amazon's marketplace that connects consumers with health benefit programs.

Recently, Teladoc partnered with Instacart to integrate its cardiometabolic programs directly to grocery access. Members can earn Instacart Health fresh funds, which are digital grocery stipends, by completing program-specific device checks like blood glucose readings or smart scale weigh-ins. Members also can add ingredients from Teladoc's curated nutrition content, like heart-healthy dinner recipes or diabetes-friendly meal plans, straight to their Instacart cart.

https://www.fiercehealthcare.com/health-tech/teladoc-health-inks-partnership-walmart-expand-virtual-care-access

Agilent beats, raises FY26 outlook as Ignite lifts margins, introduces OpenLab Sync AI

 

Agilent beats fiscal Q2 2026 estimates, raises FY26 outlook as Ignite lifts margins, introduces OpenLab Sync AI lab execution system

  • [Investor Takeaway] Q2 revenue, EPS and margins all exceeded the high end of guidance.
  • [Investor Takeaway] Ignite pricing and efficiency actions are now structurally lifting margins and earnings power.
  • [Investor Takeaway] Instrument replacement cycle and diagnostics strength drove broad-based outperformance across end markets.
  • [Investor Takeaway] Key overhangs remain China, food, and academia/government funding plus Middle East cost inflation.
  • [Key Results] Revenue $1.83B, core +6.3% YoY, reported +10%, ~80 bps above guidance high end.
  • [Key Results] EPS $1.49, +14% YoY, $0.07 above the top of guidance range.
  • [Key Results] Operating margin 26.4%, +130 bps YoY and +180 bps sequential, well above guidance.
  • [Key Results] Gross margin 55%, +90 bps YoY on volume leverage, mix and Ignite benefits.
  • [Guidance & Outlook] FY26 core growth now 4.5–6%, midpoint raised 30 bps versus prior.
  • [Guidance & Outlook] FY26 revenue $7.39–7.49B; currency now a 1.8% tailwind for the year.
  • [Guidance & Outlook] FY26 EPS $6.00–6.10, midpoint raised $0.08; implies 7–9% EPS growth.
  • [Guidance & Outlook] Q3 revenue $1.83–1.85B, core +4.4–5.9%; EPS $1.48–1.50, +8–9% YoY.
  • [Guidance & Outlook] FY26 operating margin expansion now 85 bps at midpoint, up 10 bps versus prior.
  • [Guidance & Outlook] Management describes tone as confident but prudent given tougher H2 comps and macro risks.
  • [Growth Drivers] Pharma +6% with biotech low double-digit and GLP‑1 workflows ~20% growth year-to-date.
  • [Growth Drivers] Chemicals and Advanced Materials +8%, driven by semiconductors and healthy chemical CapEx, especially in Americas.
  • [Growth Drivers] Diagnostics and Clinical +11%, led by Omnis instruments and double-digit pathology reagents growth.
  • [Growth Drivers] Environmental and forensics +13%, including >50% forensics growth and TSA airport security win.
  • [Growth Drivers] Instruments high single-digit overall; LC/LC/MS and GC both low double-digit with replacement tailwind.
  • [Growth Drivers] Book-to-bill >1 for ninth consecutive quarter, signaling continued instrument demand strength.
  • [Problem Areas] Food -3% on delayed government funding in China and India, plus Middle East pressures.
  • [Problem Areas] Academia and government -5%, with China particularly soft; U.S. stabilizing but still muted.
  • [Problem Areas] China revenue -9% in Q2; H1 roughly flat, still guided flattish for FY26.
  • [Problem Areas] Small and mid-cap biotech funding environment still challenging, though management sees early “green shoots.”
  • [Margins & Profitability] Q2 pricing contributed ~200 bps, already exceeding initial full-year 100 bps pricing goal.
  • [Margins & Profitability] Manufacturing overhead reduced by >50 bps YoY via Ignite supply-chain and operations initiatives.
  • [Margins & Profitability] Sequential Q2–Q3 operating margin expected roughly flat, then seasonally strong expansion into Q4.
  • [Margins & Profitability] Ignite-driven efficiencies expected to offset Middle East logistics and semiconductor-related inflation in H2.
  • OpenLab Sync integrates with USP MethodConnect to digitalize and standardize bench workflows in regulated labs within Agilent's OpenLab informatics portfolio.
  • [Notable Items] TSA aviation security contract ~$9M; ~$5M recognized in Q2, rest ahead of World Cup.
  • [Notable Items] Specialty CDMO “Advanced Therapeutics” grew high single digits; still guided to mid-teens FY26 growth.
  • [Notable Items] Train C CDMO facility reached mechanical completion; revenue expected to begin spring FY27.
  • [Notable Items] Biocare acquisition and potential tariff refunds are excluded from guidance; integration planning underway.
  • [Notable Items] Q2 operating cash flow $277M; capex $76M; FY26 capex now ~$450M, cut by $50M.
  • [Notable Items] Net leverage 0.7x; $65M buybacks and $72M dividends in Q2 maintain shareholder returns.
  • [Key Company-Specific Metrics] Instrument book-to-bill above 1 for nine consecutive quarters, supporting forward growth visibility.
  • [Key Company-Specific Metrics] New digital orders +9% overall, >20% ex-China, lowering transaction costs and aiding mix.
  • [Management Tone] Management is clearly confident, emphasizing structural Ignite benefits and share gains across major geographies.
  • [Management Tone] Compared with prior quarters, commentary highlighted stronger operational control and less dependence on macro recovery.
  • [Investor/Analyst Focus] Multiple questions on CAM and semiconductor demand durability and any Middle East-related impact.
  • [Investor/Analyst Focus] Margins, pricing contribution and sustainability of Ignite-driven operating leverage were a central focus.
  • [Investor/Analyst Focus] Analysts probed visibility in Advanced Therapeutics, LC/GC replacement cycle durability, diagnostics momentum and China trajectory.
  • Main concern: macro and funding headwinds in China, food, and academia/government could constrain upside to guidance.
  • Strong quarter, driven by broad-based instrument and diagnostics growth plus Ignite-led pricing and efficiency gains.

Ionis says partner GSK’s bepirovirsen met primary endpoints in two Phase 3 chronic hepatitis B trials

 


  • Ionis reports bepirovirsen achieved unprecedented functional cure rates in two Phase 3 chronic hepatitis B studies
  • Positive Phase 3 data reinforces bepirovirsen’s prospects under priority regulatory review, according to Ionis
  • Ionis highlights bepirovirsen’s success as supportive of the company’s future royalty potential from the program

CVS Restores Coverage for Eli Lilly's Zepbound

 CVS Health Corp CVS announced significant updates to its pharmacy benefits management division, CVS Caremark, which will reinstate coverage for Eli Lilly's weight-loss drug Zepbound and include the new oral medication Foundayo. This change is aimed at providing policyholders with a broader selection of GLP-1 medications and enhancing market competitiveness.

CVS Health's decision to reinstate Zepbound as a preferred medication on its formulary, effective October 1, 2026, is a strategic move following its removal in late 2024. The reinstatement comes as CVS Caremark aims to enhance its competitive edge against Novo Nordisk's Wegovy, which had previously taken precedence due to pricing considerations. Additionally, CVS Caremark will lift the new drug launch restriction on Foundayo starting June 1, 2026, allowing coverage for this newly approved oral weight-loss medication. CVS Caremark President Ed DeVaney emphasized that these changes stem from negotiations with pharmaceutical partners to improve drug affordability and accessibility, ultimately benefiting millions of Americans.

https://www.gurufocus.com/news/8888507/cvs-restores-coverage-for-eli-lillys-zepbound-cvs

FDA OKs Cogent NDA for bezuclastinib plus sunitinib in previously treated GIST, grants Priority Review

 


  • FDA set a PDUFA target action date of November 30, 2026 for the application.
  • No FDA advisory committee meeting is currently planned for the bezuclastinib plus sunitinib NDA.
  • FDA has not identified any review issues to date for the bezuclastinib plus sunitinib submission.

'Fed’s Williams Says Unclear How Productivity Boom Impacts Rates'

 


Federal Reserve Bank of New York President John Williams said it’s unclear how a lift in productivity will ultimately impact interest rates and the central bank’s policymaking.

“My answer to the question of the effects of a shift in trend productivity growth on the economy and monetary policy is, unsurprisingly, ‘it depends,’” Williams said Thursday in remarks prepared for a central banking conference in Iceland. “In particular, it depends on the nature and expected duration of the shift in question.”

https://www.bloomberg.com/news/articles/2026-05-28/fed-s-williams-says-unclear-how-productivity-boom-impacts-rates